Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295951489> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4295951489 endingPage "5" @default.
- W4295951489 startingPage "1" @default.
- W4295951489 abstract "Introduction: Endothelial cells (ECs) are critical regulators of vascular homeostasis, and their dysfunction leads to the development of atherosclerosis – the main underlying cause of cardiovascular diseases (CVDs). This dysfunction can be promoted by prolonged endothelial connexin43 hemichannel activity, which is caused by the combination of high glucose levels and cytokines IL-1β/TNF-α. WIN-55,212-2 (WIN) is a synthetic agonist of CB1/CB2 receptors and can counteract the proinflammatory effects of high glucose and IL-1β/TNF-α. We hypothesize that WIN treatment on ECs will reduce connexin43 hemichannel activity, thus preventing endothelial dysfunction and atherosclerotic progression. Methods: We will use the Apolipoprotein E Knockout (ApoE-/-) mouse model to assess the impact on atherosclerotic lesions. Hyperglycemia will be generated in these mice with Streptozotocin injections. The increased levels of glucose should induce IL-1β expression and stimulate prolonged hemichannel activity. ECs will be isolated from a subset of mice and cultured to test WIN-efficacy. ATP release will be assessed through an ATP viability assay. More in vitro assessments on subsets of ApoE-/- mice treated or not with WIN will be performed. Flow cytometry will evaluate monocyte-derived macrophage concentration and other pro and anti-inflammatory cytokines in tissue samples. Furthermore, atherosclerotic plaque volume in the aortic sinus will be quantified and characterized. Results: We expect that WIN-treated ECs will reduce ATP synthesis compared to those from the control group. Moreover, we expect to see a reduction in the inflammatory response with a consequent decrease in atherosclerotic progression. Discussion: This manuscript outlines the use of a novel compound that could prevent atherosclerosis progression. The results of this study could outline a potential mechanism that may be targeted to treat or forestall atherosclerosis progression. Conclusion: Overall, we aim to determine if WIN may not only hinder this pervasive condition but inhibit CVDs through curtailing atherosclerotic plaque development. The following steps include performing the experiment, confirming results through repetition, and using other animal models." @default.
- W4295951489 created "2022-09-16" @default.
- W4295951489 creator A5008728679 @default.
- W4295951489 date "2022-09-15" @default.
- W4295951489 modified "2023-09-25" @default.
- W4295951489 title "Reducing Atherosclerotic Plaque Development and Endothelial Hemichannel Activity with WIN-55,212-2: A Research Protocol" @default.
- W4295951489 doi "https://doi.org/10.26685/urncst.379" @default.
- W4295951489 hasPublicationYear "2022" @default.
- W4295951489 type Work @default.
- W4295951489 citedByCount "0" @default.
- W4295951489 crossrefType "journal-article" @default.
- W4295951489 hasAuthorship W4295951489A5008728679 @default.
- W4295951489 hasBestOaLocation W42959514891 @default.
- W4295951489 hasConcept C126322002 @default.
- W4295951489 hasConcept C134018914 @default.
- W4295951489 hasConcept C164027704 @default.
- W4295951489 hasConcept C170493617 @default.
- W4295951489 hasConcept C202751555 @default.
- W4295951489 hasConcept C2776914184 @default.
- W4295951489 hasConcept C2778938600 @default.
- W4295951489 hasConcept C2779134260 @default.
- W4295951489 hasConcept C2779244956 @default.
- W4295951489 hasConcept C2780972559 @default.
- W4295951489 hasConcept C2781184567 @default.
- W4295951489 hasConcept C55493867 @default.
- W4295951489 hasConcept C57089818 @default.
- W4295951489 hasConcept C71924100 @default.
- W4295951489 hasConcept C86803240 @default.
- W4295951489 hasConcept C98274493 @default.
- W4295951489 hasConceptScore W4295951489C126322002 @default.
- W4295951489 hasConceptScore W4295951489C134018914 @default.
- W4295951489 hasConceptScore W4295951489C164027704 @default.
- W4295951489 hasConceptScore W4295951489C170493617 @default.
- W4295951489 hasConceptScore W4295951489C202751555 @default.
- W4295951489 hasConceptScore W4295951489C2776914184 @default.
- W4295951489 hasConceptScore W4295951489C2778938600 @default.
- W4295951489 hasConceptScore W4295951489C2779134260 @default.
- W4295951489 hasConceptScore W4295951489C2779244956 @default.
- W4295951489 hasConceptScore W4295951489C2780972559 @default.
- W4295951489 hasConceptScore W4295951489C2781184567 @default.
- W4295951489 hasConceptScore W4295951489C55493867 @default.
- W4295951489 hasConceptScore W4295951489C57089818 @default.
- W4295951489 hasConceptScore W4295951489C71924100 @default.
- W4295951489 hasConceptScore W4295951489C86803240 @default.
- W4295951489 hasConceptScore W4295951489C98274493 @default.
- W4295951489 hasIssue "9" @default.
- W4295951489 hasLocation W42959514891 @default.
- W4295951489 hasOpenAccess W4295951489 @default.
- W4295951489 hasPrimaryLocation W42959514891 @default.
- W4295951489 hasRelatedWork W2027913950 @default.
- W4295951489 hasRelatedWork W2033472167 @default.
- W4295951489 hasRelatedWork W2034583712 @default.
- W4295951489 hasRelatedWork W2050423574 @default.
- W4295951489 hasRelatedWork W2058205365 @default.
- W4295951489 hasRelatedWork W2063619316 @default.
- W4295951489 hasRelatedWork W2070611629 @default.
- W4295951489 hasRelatedWork W2160510592 @default.
- W4295951489 hasRelatedWork W2169225653 @default.
- W4295951489 hasRelatedWork W2275976839 @default.
- W4295951489 hasVolume "6" @default.
- W4295951489 isParatext "false" @default.
- W4295951489 isRetracted "false" @default.
- W4295951489 workType "article" @default.